Mohammed E. Alomar

Cardiology

12902 Usf Magnolia Dr
Tampa, FL 33612

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 40 publications

Cardiovascular Adverse Events During Venetoclax-Based Treatment in Acute Myeloid Leukemia.

Cardiovascular Adverse Events During Venetoclax-Based Treatment in Acute Myeloid Leukemia.

Journal: Journal of the American Heart Association

Published: May 06, 2026

CGE26-142: Fluoropyrimidine-Associated Cardiotoxicity in DPYD Genetic Variants.

CGE26-142: Fluoropyrimidine-Associated Cardiotoxicity in DPYD Genetic Variants.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN

Published: April 16, 2026

CGE26-142: Fluoropyrimidine-Associated Cardiotoxicity in DPYD Genetic Variants.

CGE26-142: Fluoropyrimidine-Associated Cardiotoxicity in DPYD Genetic Variants.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN

Published: March 31, 2026

Epigenome-Wide Association Studies of Proteasome Inhibitor-Related Cardiotoxicity in Patients with Multiple Myeloma.

Epigenome-Wide Association Studies of Proteasome Inhibitor-Related Cardiotoxicity in Patients with Multiple Myeloma.

Journal: Cancers

Published: January 03, 2026

Atorvastatin Protects Against Deleterious Carfilzomib-Induced Transcriptional Changes in Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes.

Atorvastatin Protects Against Deleterious Carfilzomib-Induced Transcriptional Changes in Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes.

Journal: International journal of molecular sciences

Published: December 22, 2025

Causal Effects of Hydrophilic Bile Acids on Carfilzomib-Related Cardiovascular Events in Multiple Myeloma: A Mendelian Randomization Study.

Causal Effects of Hydrophilic Bile Acids on Carfilzomib-Related Cardiovascular Events in Multiple Myeloma: A Mendelian Randomization Study.

Journal: Clinical pharmacology and therapeutics

Published: October 14, 2025

Real-World Cardiovascular Outcomes of GLP-1 Receptor Agonists in Women With Type 2 Diabetes and Breast Cancer.

Real-World Cardiovascular Outcomes of GLP-1 Receptor Agonists in Women With Type 2 Diabetes and Breast Cancer.

Journal: Pharmacotherapy

Published: September 30, 2025

Safety and Efficacy of Tumor-Infiltrating Lymphocyte Therapy with Reduced-Dose Lymphodepleting Conditioning in High-Risk Metastatic Melanoma Patients.

Safety and Efficacy of Tumor-Infiltrating Lymphocyte Therapy with Reduced-Dose Lymphodepleting Conditioning in High-Risk Metastatic Melanoma Patients.

Journal: Transplantation and cellular therapy

Published: September 04, 2025

Real-world prevalence and outcome of elevated right ventricular systolic pressure in myelofibrosis.

Real-world prevalence and outcome of elevated right ventricular systolic pressure in myelofibrosis.

Journal: Cardio-oncology (London, England)

Published: August 23, 2025

Methylation-based biological age and cardiotoxicity risk in breast cancer patients treated with trastuzumab.

Methylation-based biological age and cardiotoxicity risk in breast cancer patients treated with trastuzumab.

Journal: Cardio-oncology (London, England)

Published: March 05, 2025

Cardiovascular adverse events and outcomes after anti-BCMA CAR-T for relapsed and refractory multiple myeloma.

Cardiovascular adverse events and outcomes after anti-BCMA CAR-T for relapsed and refractory multiple myeloma.

Journal: Blood cancer journal

Published: December 17, 2024

Unveiling the Cardiotoxicity Conundrum: Navigating the Seas of Tyrosine Kinase Inhibitor Therapies.

Unveiling the Cardiotoxicity Conundrum: Navigating the Seas of Tyrosine Kinase Inhibitor Therapies.

Journal: Cancer control : journal of the Moffitt Cancer Center

Published: September 25, 2024

Showing 1-12 of 40

Last Updated: 09/26/2026